Novocure Announces 13 Preclinical Presentations Highlighting Data on Tumor Treating Fields’ Mechanism of Action at 22nd Annual Meeting of the Society for Neuro-Oncology
An oral presentation will focus on the induction of autophagy by Tumor Treating Fields
In total, 60 abstracts on Tumor Treating Fields, including two oral presentations, will be presented
The volume of Tumor Treating Fields presentations marks a record number of abstracts for
ST. HELIER, Jersey–(BUSINESS WIRE)–
The 13 presentations include an oral presentation by Dr.
“Treatment with Tumor Treating Fields is broadly applicable and has consistently shown an antimitotic effect in our preclinical and clinical research to date,” Dr. Giladi said. “Novocure is committed to evolving our understanding of Tumor Treating Fields’ mechanism of action and potential clinical utility through the presentation of important preclinical data.”
(CBIO-16) Induction of autophagy following TTFields application serves as a survival mechanism mediated by AMPK activation. A. Shteingauz. 2:55 –
(EXTH-45) The combination of TTFields and ABT-414 demonstrate superior efficacy against glioma cells. R. Schneiderman.
(CBIO-30) Tumor treating fields (TTFields) inhibit cancer cell migration and invasion by inducing reorganizing of the actin cytoskeleton and formation of cell adhesions. R. Schneiderman.
(QLIF-20) Skin care products compatible with Tumor Treating Fields. M. Lacouture.
(EXTH-66) Glioblastoma cells from a patient post-Tumor Treating Fields (TTFields) therapy are sensitive to TTFields in vitro. S. Michelhaugh.
(CSIG-01) Tumor Treatment Fields downregulate specific transcription factors leading to reduced DNA repair capacity, increased replication stress, the inhibition of mitophagy and enhanced cell death. M. Story.
(EXTH-19) Combination of in vitro Tumor Treating Fields and temozolomide decrease proliferation in patient-derived glioblastoma cell lines. S. Michelhaugh.
(RBIO-07) Tumor Treating Fields (TTFields) Delay DNA Damage Repair Following Radiation Treatment of Glioma Cells: Implications for Irradiation through TTFields Transducer Arrays. M. Giladi.
(IMMU-59) Alternating electric fields (TTFields) induce immunogenic cell death resulting in enhanced antitumor efficacy when combined with anti-PD-1 therapy. T. Voloshin.
(IMMU-48) Evaluating the in-vitro effects of Tumor Treating Fields on T-cell responses. G. Diamant.
(PDTM-26) Tumor treating fields (TTFields) have anti-proliferative effects on pediatric brain tumor cell lines at clinically deliverable field settings. S. Smith.
(DDIS-15) Synergistic Inhibition of Glioma Cell Proliferation by Withaferin A and Tumor Treating Fields. E. Chang.
(TMIC-38) Modulation of cancer cell metabolism and immune phenotype by TTFields. E. Wong.
Headquartered in Jersey,
In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions as well as more specific risks and uncertainties facing
View source version on businesswire.com: http://www.businesswire.com/news/home/20171108005521/en/
Media and Investors:
Ashley Cordova, 212-767-7558